Collin Hovinga, PharmD, has been named to a four-year term as a member of the U.S. Food and Drug Administration’s Drug Safety and Risk Management Advisory Committee. Dr. Hovinga, SVP of Clinical and Scientific Development at I-ACT for Children, joined the organization in 2018 and plays a lead role on many of our proprietary and…
I-ACT for Children held a virtual workshop – “Developing Pediatric Treatments for COVID-19” – to discuss the progress of (and challenges related to) developing pediatric COVID-19 treatments with regulators, biopharma developers and experts on the front lines of treating children with COVID-19. Speakers shared the latest on the clinical presentation of COVID-19 in children, the…
FOR IMMEDIATE RELEASE Contact: Berna Diehl Phone: 202-725-2553 Email: berna@brightoncomms.com Article by I-ACT for Children, other leading pediatric researchers stresses urgency in addressing the questions surrounding children and the disease Rockville, MD– Increasing reports of severe COVID-19 illness in children – coupled with the fact that little is known about how and why…
I-ACT for Children Launches Emergency Access Program to Speed Pediatric Clinical Trials for COVID-19
FOR IMMEDIATE RELEASE Contact: Berna Diehl Phone: 202-725-2553 Email: berna@brightoncomms.com Emergency program will allow any company developing COVID-19 treatments or vaccines to tap into pediatric global network, trial-planning experts Rockville, MD, – As the number of children with severe COVID-19 illness grows, there is increasing urgency to ensure that potential treatments and vaccines are tested for…
The Institute for Advanced Clinical Trials (I-ACT) for Children is pleased to announce the appointment of Gary Noel, MD, as its Chief Medical Officer. Dr. Noel is a pediatrician, child advocate, specialist in Infectious Diseases and Immunology and a seasoned expert in drug development, having spent more than 30 years in leadership roles in the…
For the 28th year, SOCRA will welcome clinical research professionals from across the world. Located in San Antonio, TX at the Grand Hyatt San Antonio, this three day conference will offer current information and tools, best practices, and training to assure that you’re up-to-date and compliant in your clinical research practice. The program will feature…
The Duchenne Platform Trial is being designed to increase access to therapeutic trials across the Duchenne community, with the goals of: More rapid completion of testing and approval of new DMD therapies Reduced clinical trial start-up and execution time Enhanced patient experience, reduced number on placebo Potential for rapidly testing combination therapies The trial will…
SHERATON SILVER SPRING | SILVER SPRING, MD SEPTEMBER 9, 2019 | 8:30 AM-4:30 PM I-ACT for Children will co-host the first Duchenne Muscular Dystrophy Platform Trial Community Meeting on Sept. 9 with collaborators Parent Project Muscular Dystrophy and the Critical Path Institute. The Duchenne Platform Trial is being designed to increase access to therapeutic trials…
I-ACT for Children has selected Advarra as the central IRB for the I-ACT for Children Clinical Trials Site Network – a geographically and therapeutically diverse network of pediatric trial sites committed to improving efficiencies and capabilities for the conduct of clinical trials. I-ACT for Children launched the central IRB function to streamline processes, expedite IRB…
Today I-ACT for Children welcomes Chiesi Group as our newest Annual Member. Click on the link below for more details. Full press release